Following obtaining the Temporary Recommendation for Use (RTU) in 2015, Hospital Pharmacy Unit (HPU) manufactures syringes of Avastin® (Bevacizumab) for the treatment of Age-Related Macular Degeneration (AMD). Financial interest is major, the cost of Avastin® being definitely lower than currently used drugs for the same disease, and whose similar effectiveness has been demonstrated by several bibliographical studies.

The aim of the study is to determine the economic impact of this manufacturing syringes by HPU, from September 2016 to September 2017.

- Cost-calculation of annual Avastin® syringes productions
- Estimated the benefits obtained using manufacturated syringes
- Comparison with the cost estimated by using Lucentis® (Ranibizumab), drug having the Medicinal Market Authorization (MMA) in this therapeutic indication

Despite the losses (42.4%) due to a short expiry date, manufacturing Avastin® syringes compared to use Lucentis® generates a higher gain, nearly 6,197€.

With current consumption, this study allows to highlight manufacturing of Avastin® syringes is financially interesting in the treatment of AMD for our HPU, compared to use of Lucentis®. Nevertheless, to optimize profitability of Avastin syringes production, it would be interesting to correlate production sessions and requests in order to improve production scheduling, decrease losses and increase earnings.